Clinical Trials

506 enrolled

GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04524871 2026-02-27

MORPHEUS-LIVER

518 enrolled

Advanced Liver Cancers

NCT05083481 2026-02-27

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

366 enrolled

Advanced Solid Tumors

NCT05739981 2026-02-27

MRD

30 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03942328 2026-02-24

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

85 enrolled

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT07397819 2026-02-09

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

48 enrolled

Malignant Ascites

NCT06697197 2026-02-03

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

413 enrolled

Advanced Solid Tumors

NCT04626635 2026-02-02

COMBINE-EGFR-1

933 enrolled

Advanced Solid Tumors

NCT05867420 2026-01-27

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

594 enrolled

Advanced Solid Tumors

NCT05584670 2026-01-20

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

542 enrolled

Solid Tumor

NCT07080216 2026-01-05

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

120 enrolled

Uterine Cervical Neoplasms

NCT06512051 2025-12-23

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

248 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06730750 2025-12-15

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

360 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

NCT05956821 2025-12-08

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

20 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Oligodendroglioma

NCT06703177 2025-12-03

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

876 enrolled

Advanced Solid Tumors

NCT06311851 2025-11-25

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

40 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT07244705 2025-11-24

A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC

66 enrolled

Disease, Colorectal Neoplasms

NCT06796907 2025-10-14

BEHOLD-2

392 enrolled

Tumor-Agnostic

Neoplasms

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

40 enrolled

CRC

NCT06840002 2025-09-30

A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer

150 enrolled

Ovarian Neoplasms

NCT04486352 2025-09-04

EndoMAP

148 enrolled

Endometrial Neoplasms

NCT06953323 2025-08-13

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

86 enrolled

Advanced Solid Tumor

NCT07044908 2025-08-12

TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer

72 enrolled

RAS/BRAF Wild Type Colorectal Cancer

NCT06294548 2025-08-11

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

45 enrolled

Carcinoma, Hepatocellular

NCT07012954 2025-06-24

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

64 enrolled

Colorectal Cancer Metastatic

NCT06859775 2025-06-06

SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

100 enrolled

Uterine Cervical Neoplasms, Recurrence

NCT06995105 2025-05-29

Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma

30 enrolled

Advanced Hepatocellular Carcinoma (HCC)

NCT06922383 2025-04-15

A Clinical Study of Arfolitixorin in Patients With mCRC

60 enrolled

Colorectal Neoplasms

NCT01269853 2025-04-09

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

54 enrolled

CNS

Astrocytoma, Glioblastoma, Neoplasms

NCT06718933 2025-02-06

Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

74 enrolled

Breast

Breast Cancer Metastatic

NCT06782685 2025-01-20

Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV

138 enrolled

Advanced Pancreatic Cancer (Part 1)

NCT06139211 2024-12-20

A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors

186 enrolled

Advanced Solid Tumor

NCT06725121 2024-12-16

MacroTrans

48 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05640830 2024-11-26

TREAZURE

47 enrolled

HER2-positive Advanced Gastric Cancer

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

DermatologicGastrointestinalGenitourinarySarcoma

358 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT06241235 2024-04-02

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

48 enrolled